Business Information
The group's principal activity is to create tools that drive the genomic revolution. The group has developed genechip-tm system for analyzing and managing genetic information. The genechip(R) platform consists of disposable dna probe arrays containing gene sequence, certain reagents for use with the probe arrays, a scanner and other instruments. The products are sold to pharmaceutical, biotechnology, agrochemical, diagnostics and consumer products companies and also to academic research centers, private foundations and clinical laboratories in the United States, Europe and Japan.
|
|
Name |
Title
|
Email
|
| Stephen Fodor | Chmn., CEO | N/A | | Barbara Caulfield | Exec. VP, General Counsel | N/A | | Doug Farrell | VP - Investor Relations | N/A | | John Batty | CFO, Exec. VP - Finance | N/A | | Kevin King | Pres. - Life Sciences Business, Exec. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 355,317 | (13,704) | | 2005 | 367,602 | 65,787 | | 2004 | 345,962 | 47,608
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
